Uptake of care and treatment amongst a national cohort of HIV positive infants diagnosed at primary care level, South Africa.
Adult
Anti-Retroviral Agents
/ economics
CD4 Lymphocyte Count
Female
Follow-Up Studies
HIV
/ immunology
HIV Infections
/ diagnosis
HIV Seropositivity
Health Care Costs
Health Knowledge, Attitudes, Practice
Humans
Infant
Infectious Disease Transmission, Vertical
/ prevention & control
Lost to Follow-Up
Male
Mothers
Postnatal Care
Pregnancy
Primary Health Care
Prospective Studies
Self Report
South Africa
Young Adult
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
16 Sep 2019
16 Sep 2019
Historique:
entrez:
19
9
2019
pubmed:
19
9
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Loss to follow-up after a positive infant HIV diagnosis negates the potential benefits of robust policies recommending immediate triple antiretroviral therapy initiation in HIV positive infants. Whilst the diagnosis and follow-up of HIV positive infants in urban, specialized settings is easier to institutionalize, there is little information about access to care amongst HIV positive children diagnosed at primary health care clinic level. We sought to understand the characteristics of HIV positive children diagnosed with HIV infection at primary health care level, across all provinces of South Africa, their attendance at study-specific exit interviews and their reported uptake of HIV-related care. The latter could serve as a marker of knowledge, access or disclosure. Secondary analysis of data gathered about HIV positive children, participating in an HIV-exposed infant national observational cohort study between October 2012 and September 2014, was undertaken. HIV infected children were identified by total nucleic acid polymerase chain reaction using standardized procedures in a nationally accredited central laboratory. Descriptive analyses were conducted on the HIV positive infant population, who were treated as a case series in this analysis. Data from interviews conducted at baseline (six-weeks post-delivery) and on study exit (the first visit following infant HIV positive diagnosis) were analysed. Of the 2878 HIV exposed infants identified at 6 weeks, 1803 (62.2%), 1709, 1673, 1660, 1680 and 1794 were see at 3, 6, 9, 12, 15 and 18 months respectively. In total, 101 tested HIV positive (67 at 6 weeks, and 34 postnatally). Most (76%) HIV positive infants were born to single mothers with a mean age of 26 years and an education level above grade 7 (76%). Although only 33.7% of pregnancies were planned, 83% of mothers reported receiving antiretroviral drugs to prevent MTCT. Of the 44 mothers with a documented recent CD4 cell count, the median was 346.8 cell/mm Early ART uptake amongst children aged 15 months and below was low. This raises questions about timely, early paediatric ART uptake amongst HIV positive children diagnosed in primary health care settings. Qualitative work is needed to understand low and delayed paediatric ART uptake in young children, and more work is needed to measure progress with infant ART initiation at primary care level since 2014.
Sections du résumé
BACKGROUND
BACKGROUND
Loss to follow-up after a positive infant HIV diagnosis negates the potential benefits of robust policies recommending immediate triple antiretroviral therapy initiation in HIV positive infants. Whilst the diagnosis and follow-up of HIV positive infants in urban, specialized settings is easier to institutionalize, there is little information about access to care amongst HIV positive children diagnosed at primary health care clinic level. We sought to understand the characteristics of HIV positive children diagnosed with HIV infection at primary health care level, across all provinces of South Africa, their attendance at study-specific exit interviews and their reported uptake of HIV-related care. The latter could serve as a marker of knowledge, access or disclosure.
METHODS
METHODS
Secondary analysis of data gathered about HIV positive children, participating in an HIV-exposed infant national observational cohort study between October 2012 and September 2014, was undertaken. HIV infected children were identified by total nucleic acid polymerase chain reaction using standardized procedures in a nationally accredited central laboratory. Descriptive analyses were conducted on the HIV positive infant population, who were treated as a case series in this analysis. Data from interviews conducted at baseline (six-weeks post-delivery) and on study exit (the first visit following infant HIV positive diagnosis) were analysed.
RESULTS
RESULTS
Of the 2878 HIV exposed infants identified at 6 weeks, 1803 (62.2%), 1709, 1673, 1660, 1680 and 1794 were see at 3, 6, 9, 12, 15 and 18 months respectively. In total, 101 tested HIV positive (67 at 6 weeks, and 34 postnatally). Most (76%) HIV positive infants were born to single mothers with a mean age of 26 years and an education level above grade 7 (76%). Although only 33.7% of pregnancies were planned, 83% of mothers reported receiving antiretroviral drugs to prevent MTCT. Of the 44 mothers with a documented recent CD4 cell count, the median was 346.8 cell/mm
CONCLUSIONS
CONCLUSIONS
Early ART uptake amongst children aged 15 months and below was low. This raises questions about timely, early paediatric ART uptake amongst HIV positive children diagnosed in primary health care settings. Qualitative work is needed to understand low and delayed paediatric ART uptake in young children, and more work is needed to measure progress with infant ART initiation at primary care level since 2014.
Identifiants
pubmed: 31526376
doi: 10.1186/s12879-019-4342-3
pii: 10.1186/s12879-019-4342-3
pmc: PMC6745775
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
790Références
S Afr Med J. 2012 Dec 31;103(4):232-6
pubmed: 23547688
J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):e122-8
pubmed: 21224736
J Epidemiol Community Health. 2015 Mar;69(3):240-8
pubmed: 25371480
PLoS One. 2012;7(12):e51289
pubmed: 23240013
S Afr Med J. 2014 Mar;104(3 Suppl 1):239-43
pubmed: 24893500
AIDS. 2012 Dec;26 Suppl 2:S105-16
pubmed: 23303433
Trop Med Int Health. 2008 Jul;13(7):904-13
pubmed: 18466183
J Int AIDS Soc. 2013 Jan 02;16:17994
pubmed: 23336727
Afr Health Sci. 2012 Sep;12(3):318-24
pubmed: 23382746
Cochrane Database Syst Rev. 2013 Jun 27;(6):CD009987
pubmed: 23807693
N Engl J Med. 2011 Aug 18;365(7):581-3
pubmed: 21848457
J Glob Health. 2016 Dec;6(2):020405
pubmed: 27698999
N Engl J Med. 2008 Nov 20;359(21):2233-44
pubmed: 19020325
J Acquir Immune Defic Syndr. 2012 Aug 15;60 Suppl 3:S105-12
pubmed: 22797731
AIDS Care. 2014 Apr;26(4):425-33
pubmed: 24090313
J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e95-103
pubmed: 24525473
AIDS. 2013 Nov;27 Suppl 2:S197-205
pubmed: 24361629
J Clin Microbiol. 2012 Jul;50(7):2373-7
pubmed: 22518871